Company Overview of Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. produces and markets keyhole limpet hemocyanin (KLH), as well as develops technology related to the culture and production of KLH and subunit KLH formulations in the United States and Europe. The company’s KLH is an immunogenic high-molecular-weight protein, which is used in cancers and therapeutic vaccines for lymphoma, bladder, breast, colon, and other cancers. Its KLH products include pharmaceutical intermediates and research regents, as well as products for vaccine conjugation. The company also provides KLH ELISA test kits used for the quantitative measure of anti-KLH antibodies in serum or plasma samples. Stellar Biotechnologies, Inc. is headquartered in Po...
332 East Scott Street
Port Hueneme, CA 93041
Key Executives for Stellar Biotechnologies, Inc.
Total Annual Compensation: $334.3K
Chief Operations Officer
Total Annual Compensation: $142.1K
Chief Technology Officer
Total Annual Compensation: $160.9K
Compensation as of Fiscal Year 2012.
Stellar Biotechnologies, Inc. Key Developments
Stellar Biotechnologies, Inc. - Special Call
Dec 3 13
To review the significant milestones achieved in 2013 including its acquisition of exclusive rights to an innovative KLH-based immunotherapy technology to treat Clostridium difficile infection, as well as recent manufacturing and R&D progress and company's plans for expansion involving potential catalysts in R&D, manufacturing and business development
Stellar Biotechnologies, Inc. Appoints Mark A. Mcpartland as Vice President of Corporate Development and Communications
Nov 20 13
Stellar Biotechnologies, Inc. announced the appointment of Mark A. McPartland as Vice President of Corporate Development and Communications. Mr. McPartland will report to Frank Oakes, President and CEO of the company. Mr. McPartland will lead Stellar's corporate development and investor-related programs including management of stakeholder relationships, commercial collaborating, capital markets strategy, external communications, media relations, and public affairs. Additionally, he will collaborate in the development of corporate strategy and serve as primary point of contact to the investment community. Mr. McPartland joins Stellar with over 16 years experience in business development, capital markets advisory, corporate communications and C-suite consulting.
Stellar Biotechnologies Announces Two Key Appointments
Nov 5 13
Stellar Biotechnologies, Inc. announced the appointment of two of the company's senior executives to expanded leadership positions. Kathi Niffenegger, CPA has been appointed as Chief Financial Officer and Catherine Brisson, Ph.D. has been appointed as Chief Operations Officer. Stellar's board of directors voted unanimously to promote Ms. Niffenegger and Ms. Brisson to strengthen the company's financial oversight and operational efficiency. Ms. Niffenegger began working with Stellar in 1999, as outside CPA. She became Controller for Stellar Biotechnologies in 2012 and assumed the role of Corporate Secretary earlier this year. Dr. Brisson joined Stellar in 2010 as Director of Quality and Regulatory Affairs, and was promoted to Chief Pharmaceutical Officer in 2012. She has more than 20 years of experience in the biotechnology, pharmaceutical and medical device industries with strong expertise and broad scientific and operational understanding in quality assurance, quality control, regulatory affairs, manufacturing, and product development areas.
Similar Private Companies By Industry
Recent Private Companies Transactions